CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growth in the biologics sector
4.1.2. High occurrence rate of lifestyle diseases
4.1.3. Rising adoption of protein-based drugs over non-protein-based drugs
4.1.4. Growing protein’s stability and circulating half-life
4.2. Market Restraints & Challenges
4.2.1. Increasing market merging increases entry barriers
4.2.2. Drug failure and recalls hinders market growth
4.3. Market Opportunities
4.3.1. Patent expiry of top-selling drugs shortly
4.3.2. Growing opportunities in emerging markets
CHAPTER 5. GLOBAL PEGYLATED PROTEINS MARKET – BY PRODUCT
5.1. Consumables
5.1.1 Pegylation Kits
5.1.2 Pegylation Reagents
5.1.2.1 Monofunctional Linear Pegs
5.1.2.2 Bifunctional Pegs
5.1.2.3 Multi-Arm Pegs
5.1.2.4 Branched Pegs
5.1.2.5 Other Pegylation Reagents
5.2. Services
5.2.1 Development of PEGylated Biosimilar
5.2.2 Process Development of Peg-Drug Conjugate Manufacturing
5.2.3 Pilot Production of Peg Drug Conjugate
5.2.4 Development of Analytical Methods
5.2.5 Pegylation Feasibility Studies
CHAPTER 6. GLOBAL PEGYLATED PROTEINS MARKET – BY PROTEIN TYPE
6.1. Colongy Stimulating Factors
6.2. Interferons
6.3. Erythropoietin (EPO)
6.4. Recombinant Factor Viii
6.5. Monoclonal Antibodies
6.6. Other Protein Type
CHAPTER 7. GLOBAL PEGYLATED PROTEINS MARKET – BY APPLICATION
7.1. Cancer Treatment
7.2. Hepatitis
7.3. Chronic Kidney Disease
7.4. Haemophilia
7.5. Multiple Sclerosis
7.6. Gastrointestinal Disorder
CHAPTER 8. GLOBAL PEGYLATED PROTEINS MARKET – BY END USER
8.1. Pharmaceutical & Biotechnology Companies
8.2. Contract Research Organization
8.3. Academic Research Institutes
CHAPTER 9. GLOBAL PEGYLATED PROTEINS MARKET – BY DISTRIBUTION
CHANNEL
9.1. Hospital pharmacies
9.2. Online provider
9.3. Retail Pharmacy
CHAPTER 10. GLOBAL PEGYLATED PROTEINS MARKET - BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.2.4. Costa Rica
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Chile
10.3.4. Columbia
10.3.5. Others
10.4. Europe
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Russia
10.4.7. Netherlands
10.4.8. Switzerland
10.4.9. Poland
10.4.10. Others
10.5. APAC
10.5.1. China
10.5.2. Japan
10.5.3. India
10.5.4. South Korea
10.5.5. Australia & New Zealand
10.5.6. Malaysia
10.5.7. Singapore
10.5.8. Others
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. Iran
10.6.4. Iraq
10.6.5. Qatar
10.6.6. South Africa
10.6.7. Algeria
10.6.8. Morocco
10.6.9. Nigeria
10.6.10. Egypt
10.6.11. Others
CHAPTER 11. GLOBAL PEGYLATED PROTEINS MARKET - COMPANY
PROFILES
11.1. Thermo Scientific Fisher, Inc.
11.2. Jenkem Technology
11.3. Celeres GmbH Creative Peg works
11.4. Quanta Bio design, Ltd
11.5. Biomatrik, Inc.
11.6. Creative Peg works
11.7.NOF American Corporation
11.8. Iris Biotech GmbH
11.9. Laysan Bio, Inc.
11.10. Merck Millipore
11.11. Crealta Pharmaceuticals LLC
11.12. ENZON Pharmaceuticals, Inc
11.13. UCB Research Company
11.14. Merck & Company, Inc.
CHAPTER 12. GLOBAL PEGYLATED PROTEINS MARKET - COMPETITIVE
LANDSCAPE
12.1. Market Share Analysis
12.2. Strategies adopted by top companies
12.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 13. MARKET INSIGHTS
13.1. Industry Experts Insights
13.2. Analysts Opinions
13.3. Investment Opportunities
CHAPTER 14. APPENDIX
14.1. List of Tables
14.2. List of Figures
